SCHEMBL7943380

SCHEMBL7943380

Cc1c(C(=O)Nc2ccc(F)c(C3(C)CC(=O)N(C)C(N)=N3)c2)oc2ccc(F)cc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 12/20 0.53
HCRTR1 O43613 1/20 0.48
PPARG P37231 1/20 0.48
NCOR2 Q9Y618 1/20 0.48
BACE2 Q9Y5Z0 5/20 0.46
KCNH2 Q12809 1/20 0.46
DGAT1 O75907 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAPT P10636 2/20 0.44
THRB P10828 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12302218 0.94 BACE1 (0.53) BACE1BACE2KCNH2DGAT1MAPT
SCHEMBL7942669 0.93 BACE1 (0.54) BACE1BACE2PTGDR2RXFP1
SCHEMBL7933972 0.93 BACE1 (0.52) BACE1BACE2KCNH2MAPTKDM4E
SCHEMBL7943378 0.92 BACE1 (0.62) BACE1BACE2NPC1RAB9AMAPT
SCHEMBL7944999 0.91 BACE1 (0.54) BACE1HCRTR1BACE2NPC1RAB9A
SCHEMBL7944886 0.91 BACE1 (0.52) BACE1BACE2DGAT1PTGDR2NPC1
SCHEMBL7941920 0.87 BACE1 (0.57) BACE1HCRTR1PPARGNCOR2BACE2
SCHEMBL7944678 0.86 RAB9A (0.47) BACE1HCRTR1PPARGNCOR2DGAT1
SCHEMBL7934603 0.85 BACE1 (0.53) BACE1BACE2KCNH2
SCHEMBL12301677 0.81 BACE1 (0.59) BACE1BACE2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885HCRTR1 1057/4885PPARG 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.